In this video interview, Kate Gallin Heffernan, life sciences attorney at Epstein Becker Green, explains how clinical research teams can accurately report on diversity-related grant work while minimizing exposure to False Claims Act scrutiny, by focusing on precise language and framing.
In a recent video interview with Applied Clinical Trials, Kate Gallin Heffernan, life sciences attorney, Epstein Becker Green, discussed the challenges clinical research teams face with compliance due to evolving executive orders and federal funding policies. She highlighted the confusion and increased scrutiny on research projects, particularly those involving diverse populations. Practical risks include potential legal scrutiny and funding agency actions. Heffernan also emphasized the importance of accurate reporting and careful documentation to avoid false claims. Future-proofing compliance involves thorough portfolio assessments, diversifying funding sources, and strengthening partnerships between academia and industry to support early-stage research and innovation.
ACT: There’s growing concern around including DEI-related language in reporting. How can research teams acknowledge diversity-focused efforts without inadvertently increasing their exposure to legal scrutiny, such as False Claims Act risk?
Heffernan: This is a great question, and an area that I think we've seen some of the most concern expressed by clients. Many of our clients are in a really challenging position when they have to currently report on the completion of aims within a grant or within a trial project that were previously approved and designed at a time when there was both acceptance of and even really a mandate for diversity centered aspects of federally funded research. One thing that I think is important for organizations to remember, is that it's really fundamentally important for them to be accurate in how they report out the work that they've done. You can really put yourself in a False Claims bind by misrepresenting in any way the work that was done on a grant in a way that's inaccurate, that said, the way you frame that, the way you phrase it, the way in which organizations can accomplish that type of progress reporting on previously defined scopes that involved diversity efforts and mandates and avoid hot button trigger words. Those are the important considerations that we're helping clients to navigate.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Issues Complete Response Letter to Replimune for RP1 Combination Therapy in Advanced Melanoma
July 22nd 2025The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not an adequate, well-controlled study and that its heterogeneous patient population limited interpretability, preventing approval in its current form.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.